Not currently recruiting at University of California Health
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Irvine
- Dates
- study startedcompletion around
- Principal Investigator
- by Namita Goyal, MD (uci)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Namita Goyal, MD (uci)
Clinical Professor, Neurology, School of Medicine. Authored (or co-authored) 54 research publications
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- UniQure Biopharma B.V.
- ID
- NCT06100276
- Phase
- Phase 1/2 Amyotropic Lateral Sclerosis (ALS) Research Study
- Study Type
- Interventional
- Participants
- Expecting 20 study participants
- Last Updated